Does the media favor RARE or DMAC?

In the previous week, Ultragenyx Pharmaceutical had 35 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 37 mentions for Ultragenyx Pharmaceutical and 2 mentions for DiaMedica Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.73 beat DiaMedica Therapeutics' score of 0.67 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 12 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, AVBP or DMAC?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A

Is AVBP or DMAC more profitable?

ArriVent BioPharma's return on equity of -50.26% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -50.26% -46.66% DiaMedica Therapeutics N/A -77.76% -69.43%

Does the media prefer AVBP or DMAC?

In the previous week, ArriVent BioPharma had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for ArriVent BioPharma and 2 mentions for DiaMedica Therapeutics. ArriVent BioPharma's average media sentiment score of 1.08 beat DiaMedica Therapeutics' score of 0.67 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, AAPG or DMAC?

DiaMedica Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $642.64M 2.26 -$177.71M N/A N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A

Is AAPG or DMAC more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A DiaMedica Therapeutics N/A -77.76% -69.43%

Which has preferable earnings & valuation, DMAC or DMRA?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A

Is DMAC or DMRA more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86%

Which has better valuation and earnings, DMAC or TRAX?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A

Is DMAC or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% First Tracks Biotherapeutics N/A N/A N/A

Does the media prefer DMAC or TRAX?

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for First Tracks Biotherapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.67 beat First Tracks Biotherapeutics' score of 0.38 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive First Tracks Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DiaMedica Therapeutics (DMAC) Competitors

$7.56 -0.22 (-2.83%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$7.56 0.00 (0.00%)

As of 09/23/2026 04:10 PM Eastern

Compare

DMAC vs. RARE, AVBP, AAPG, DMRA, and TRAX

Should you buy DiaMedica Therapeutics stock or one of its competitors? DiaMedica Therapeutics's main competitors and comparable companies include Ultragenyx Pharmaceutical (RARE), ArriVent BioPharma (AVBP), Ascentage Pharma Group International (AAPG), Damora Therapeutics, Inc. Common Stock (DMRA), and First Tracks Biotherapeutics (TRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DiaMedica Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

DiaMedica Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. DiaMedica Therapeutics' return on equity of -77.76% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Ultragenyx Pharmaceutical had 35 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 37 mentions for Ultragenyx Pharmaceutical and 2 mentions for DiaMedica Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.73 beat DiaMedica Therapeutics' score of 0.67 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	2.18	-$575M	-$5.84	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Ultragenyx Pharmaceutical presently has a consensus price target of $34.58, suggesting a potential upside of 132.39%. DiaMedica Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 58.73%. Given Ultragenyx Pharmaceutical's higher possible upside, research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Ultragenyx Pharmaceutical beats DiaMedica Therapeutics on 10 of the 16 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

ArriVent BioPharma has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

ArriVent BioPharma currently has a consensus target price of $44.86, suggesting a potential upside of 48.04%. DiaMedica Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 58.73%. Given DiaMedica Therapeutics' higher possible upside, analysts plainly believe DiaMedica Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ArriVent BioPharma had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for ArriVent BioPharma and 2 mentions for DiaMedica Therapeutics. ArriVent BioPharma's average media sentiment score of 1.08 beat DiaMedica Therapeutics' score of 0.67 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma's return on equity of -50.26% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

Summary

ArriVent BioPharma beats DiaMedica Therapeutics on 9 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 2 mentions for DiaMedica Therapeutics and 1 mentions for Ascentage Pharma Group International. DiaMedica Therapeutics' average media sentiment score of 0.67 beat Ascentage Pharma Group International's score of -0.35 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

Ascentage Pharma Group International presently has a consensus target price of $46.43, suggesting a potential upside of 198.67%. DiaMedica Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 58.73%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, research analysts clearly believe Ascentage Pharma Group International is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ascentage Pharma Group International has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

DiaMedica Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$642.64M	2.26	-$177.71M	N/A	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Summary

Ascentage Pharma Group International beats DiaMedica Therapeutics on 7 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

DiaMedica Therapeutics (NASDAQ:DMAC) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

DiaMedica Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 58.73%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $44.00, suggesting a potential upside of 115.26%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

DiaMedica Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

In the previous week, Damora Therapeutics, Inc. Common Stock had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Damora Therapeutics, Inc. Common Stock and 2 mentions for DiaMedica Therapeutics. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.71 beat DiaMedica Therapeutics' score of 0.67 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics' return on equity of -77.76% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Damora Therapeutics, Inc. Common Stock beats DiaMedica Therapeutics on 9 of the 14 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to First Tracks Biotherapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for First Tracks Biotherapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.67 beat First Tracks Biotherapeutics' score of 0.38 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
First Tracks Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DiaMedica Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 58.73%. First Tracks Biotherapeutics has a consensus price target of $66.55, indicating a potential upside of 81.52%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

First Tracks Biotherapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
First Tracks Biotherapeutics	N/A	N/A	N/A

Summary

First Tracks Biotherapeutics beats DiaMedica Therapeutics on 6 of the 11 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAC vs. The Competition

Export

Metric	DiaMedica Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$419.54M	$3.98B	$7.31B	$13.28B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-10.50	13.88	274.10	25.70
Price / Sales	N/A	1,437.48	672.61	90.85
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	7.00	15.45	10.48	6.32
Net Income	-$32.77M	-$22.82M	$3.49B	$359.73M
7 Day Performance	10.36%	-1.68%	-0.68%	0.17%
1 Month Performance	15.95%	-6.15%	-3.18%	-3.27%
1 Year Performance	10.36%	30.67%	15.13%	5.58%

DiaMedica Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.9006 of 5 stars	$7.56 -2.8%	$12.00 +58.7%	+10.2%	$419.54M	N/A	N/A	35
RARE Ultragenyx Pharmaceutical	3.4077 of 5 stars	$14.51 +0.1%	$34.42 +137.2%	-47.6%	$1.43B	$673M	N/A	1,371	Analyst Forecast High Trading Volume
AVBP ArriVent BioPharma	2.3832 of 5 stars	$28.90 +1.9%	$44.86 +55.2%	+65.8%	$1.43B	N/A	N/A	77	Positive News Analyst Forecast Gap Up High Trading Volume
AAPG Ascentage Pharma Group International	2.9649 of 5 stars	$15.06 -2.0%	$46.43 +208.3%	-59.2%	$1.41B	$82.10M	N/A	767
DMRA Damora Therapeutics, Inc. Common Stock	3.0014 of 5 stars	$22.59 -0.8%	$44.00 +94.8%	+384.4%	$1.39B	N/A	N/A	40	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. RARE, AVBP, AAPG, DMRA, and TRAX

How does DiaMedica Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

Summary

How does DiaMedica Therapeutics compare to Ascentage Pharma Group International?

Summary

How does DiaMedica Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does DiaMedica Therapeutics compare to First Tracks Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. RARE, AVBP, AAPG, DMRA, and TRAX

How does DiaMedica Therapeutics compare to Ultragenyx Pharmaceutical?

Which has more risk and volatility, RARE or DMAC?

Is RARE or DMAC more profitable?

Do institutionals and insiders have more ownership in RARE or DMAC?

Does the media favor RARE or DMAC?

Which has stronger valuation & earnings, RARE or DMAC?

Do analysts recommend RARE or DMAC?

Summary

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

Which has more risk & volatility, AVBP or DMAC?

Do analysts recommend AVBP or DMAC?

Which has stronger earnings & valuation, AVBP or DMAC?

Do insiders & institutionals hold more shares of AVBP or DMAC?

Does the media prefer AVBP or DMAC?

Is AVBP or DMAC more profitable?

Summary

How does DiaMedica Therapeutics compare to Ascentage Pharma Group International?

Do insiders and institutionals hold more shares of AAPG or DMAC?

Does the media prefer AAPG or DMAC?

Is AAPG or DMAC more profitable?

Do analysts recommend AAPG or DMAC?

Which has more volatility & risk, AAPG or DMAC?

Which has better valuation & earnings, AAPG or DMAC?

Summary

How does DiaMedica Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Which has preferable earnings & valuation, DMAC or DMRA?

Do analysts rate DMAC or DMRA?

Which has more volatility & risk, DMAC or DMRA?

Does the media favor DMAC or DMRA?

Is DMAC or DMRA more profitable?

Do insiders & institutionals have more ownership in DMAC or DMRA?

Summary

How does DiaMedica Therapeutics compare to First Tracks Biotherapeutics?

Which has better valuation and earnings, DMAC or TRAX?

Do insiders and institutionals hold more shares of DMAC or TRAX?

Does the media prefer DMAC or TRAX?

Do analysts rate DMAC or TRAX?

Is DMAC or TRAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools